CETUXIMAB , MK-1084, MK-1084, MK-1084, MK-1084
MK-1084-014
Phase 2 small_molecule active
Quick answer
CETUXIMAB , MK-1084, MK-1084, MK-1084, MK-1084 for Neoplasm malignant with KRAS G12C mutation is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Neoplasm malignant with KRAS G12C mutation
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active